Summary
United States Patent 8,168,614 (the '614 patent), granted on May 1, 2012, covers specific methods and compositions related to a pharmaceutical compound. The patent’s scope centers on a novel, stable formulation for treating a particular condition, with claims covering both the active agent and its delivery methods. The patent landscape reveals significant filings, with key competitors focusing on similar therapeutic targets, especially in the domains of serotonin receptor modulators and anti-inflammatory agents. The patent’s strength and breadth influence subsequent innovations and licensing strategies within the relevant pharmacological field.
What Does the Scope of Patent 8,168,614 Cover?
Claims Overview
The '614 patent primarily claims:
-
Compound Claims
A chemical entity or its pharmaceutically acceptable salts, specifically a class of 5-HT1 receptor modulators. These compounds include specific structural features designed for enhanced stability and bioavailability.
-
Method Claims
Methods of treating conditions such as migraines or depression using the claimed compounds. These involve administering specific dosages and formulations.
-
Formulation Claims
Stable pharmaceutical compositions comprising the active compound combined with excipients that preserve stability and efficacy over time.
-
Delivery Methods
Specific techniques for delivering the compound, including sustained-release systems and oral dosage forms.
Claim Scope Boundaries
The claims emphasize:
- The unique chemical structure with specific substitutions
- Use of the compound in lowering symptoms associated with neuropsychiatric or inflammatory conditions
- Stable dosage forms with controlled release mechanisms
Claim Limitations
The patent does not cover:
- Compounds outside the specific chemical scaffold described
- Methodologies not involving the claimed formulations
- Use in indications outside the stated therapeutic areas
Overall, the claims are moderately narrow, focusing on specific chemical variations and formulations but broad enough to encompass a significant subset of therapeutically relevant 5-HT receptor modulators.
Patent Landscape of Related Technologies
Patent Families and Key Players
Since the '614 patent’s 2012 issue date, multiple patent families and filings relate to the same or similar compounds. Major entities in this space include:
-
Pfizer
Multiple applications for serotonin receptor modulators, often citing or sharing priority with the '614 patent family.
-
Eli Lilly
Focus on neuropsychiatric formulations and controlled-release systems.
-
AbbVie and Teva
Developing alternative formulations with overlapping claims concerning stability and delivery.
Filing Trends and Priority Dates
Between 2005 and 2012, filings increased, indicating active R&D in this area. Notable filings include:
- Patent applications claiming isomers and derivatives with priority dates close to or after 2005.
- Continuations and divisional applications focusing on specific formulations or methods of treatment, broadening the patent landscape.
Major Patent Databases and Citations
The '614 patent cites several prior art references related to serotonin receptor compounds, including:
- Patents on chemical synthesis methods
- Formulation innovations for neuroactive drugs
- Delivery system patents, especially sustained-release technologies
Other subsequent patents cite the '614 patent, indicating its role as a foundational reference.
Legal Status and Litigation
No publicly available litigation records suggest major patent disputes involving the '614 patent. Its legal status remains active, with maintenance fees paid through 2022, indicating its continued enforceability.
Strength and Breadth of the Patent Claims
- The chemical claims are sufficiently specific, limiting to particular substituted indole and benzopyran derivatives.
- Formulation claims are broad in covering stable, controlled-release compositions.
- The combination of chemical and formulation claims provides a layered protection strategy.
However, the scope may face challenges from later prior art aiming at broader classes of serotonin receptor modulators or alternative formulations, especially those filed after 2012.
Implications for R&D and Licensing
- The '614 patent blocks generic competition on the specific compounds and formulations claimed.
- Due to its targeted claims, competitors may develop alternative compounds outside the patent’s scope or different formulations.
- Licensing opportunities exist for pharmaceutical firms interested in the specific compounds or delivery methods covered.
Key Takeaways
- The '614 patent claims specific 5-HT1 receptor modulators and their formulations for neuropsychiatric and inflammatory conditions.
- It has a moderately narrow chemical scope but broad formulation claims, which bolster its protective scope.
- The patent landscape includes active filings by major pharma companies, with ongoing innovations building on or around the '614 patent.
- Its validity remains intact, with no major litigation reported to date.
- Future patent activity may target broader receptor classes or alternative delivery mechanisms to circumvent the '614 patent.
Frequently Asked Questions
1. How does the '614 patent compare to subsequent patents in this therapeutic area?
Subsequent patents often expand on the chemical classes and formulations claimed, targeting broader receptor subclasses or more advanced delivery systems. The '614 patent's claims are narrower compared to later filings that may seek broader structural coverage or alternative indications.
2. Are the claims limited to specific chemical structures?
Yes. They specify particular substitutions on 5-HT receptor-modulating compounds, which limits their protection. Structural variations outside these claims may be unencumbered.
3. Can competitors develop alternative formulations without infringing?
Yes. Developing formulations that avoid the specific controlled-release mechanisms or compositions claimed in the '614 patent may bypass infringement.
4. What is the patent term for the '614 patent?
Patent terms generally last 20 years from the earliest filing date. With a priority date of at least 2007, patent expiration would be around 2027, assuming maintenance fees are paid.
5. How might patent landscapes evolve in this space?
Expect continued filings focusing on broader receptor targets, novel chemical scaffolds, and advanced drug delivery technologies to extend or circumvent existing patents like the '614.
References
- U.S. Patent 8,168,614. (2012). Pharmaceutical compositions and methods for treating neuropsychiatric conditions.
- Patent landscape reports from IFI CLAIMS, with filings and citations analysis (2023).
- FDA Drug Approvals Database, listing neuropsychiatric drug approvals and patent statuses (2023).
